Evommune, Inc. (EVMN)
Evommune will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Evommune Revenue
Evommune had revenue of $3.00M in the twelve months ending June 30, 2025. In the year 2024, Evommune had annual revenue of $7.00M with 40.00% growth.
Revenue (ttm)
$3.00M
Revenue Growth
+40.00%
P/S Ratio
n/a
Revenue / Employee
$66,667
Employees
45
Market Cap
n/a
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.00M | 2.00M | 40.00% |
| Dec 31, 2023 | 5.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionEVMN News
- 1 day ago - Evommune files for IPO to advance immune drug work - BioPharma Dive
- 2 days ago - Evommune IPO Registration Document (S-1) - SEC
- 2 days ago - Chronic inflammatory disease biotech Evommune files for a $100 million IPO - Renaissance Capital